title: Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
abstract: Cavitary pneumonia caused by Rhodococcus equi may occur in patients with defective cell-mediated immunity. Prolonged CD4 lymphopenia may develop in patients with chronic lymphocytic leukemia who receive fludarabine. The authors report the first case of a patient with chronic lymphocytic leukemia who developed R equi pneumonia after fludarabine therapy.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Gelfand
authors.forename: Kerry O
authors.initials: KO
authors.lastname: Cleveland
authors.forename: Susan C
authors.initials: SC
authors.lastname: Brewer
mesh_terms: D000193:Actinomycetales Infections / Q000188:drug therapy / Q000382:microbiology*; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008231:Lymphopenia / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D016929:Rhodococcus equi / Q000302:isolation & purification*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine